Bristol Myers Squibb has started a Phase 1 trial of BMS‑986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma. The move brings the first jointly developed “molecular glue” candidate from the companies’ protein‑degradation partnership into human testing. The study also triggers a $10 million milestone payment to Evotec SE. BMS‑986506 emerged from a collaboration that combines Evotec’s multi‑omics and AI‑enabled discovery platforms with Bristol Myers Squibb’s library of ...